[go: up one dir, main page]

DK0787492T3 - Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress - Google Patents

Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress

Info

Publication number
DK0787492T3
DK0787492T3 DK97100145T DK97100145T DK0787492T3 DK 0787492 T3 DK0787492 T3 DK 0787492T3 DK 97100145 T DK97100145 T DK 97100145T DK 97100145 T DK97100145 T DK 97100145T DK 0787492 T3 DK0787492 T3 DK 0787492T3
Authority
DK
Denmark
Prior art keywords
nitroxides
oxidative stress
oxazolidines
protection against
ionizing radiation
Prior art date
Application number
DK97100145T
Other languages
English (en)
Inventor
William G Degraff
James B Mitchell
Stephen Hahn
Amram Samuni
Original Assignee
Us Secretary United States Dep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Secretary United States Dep filed Critical Us Secretary United States Dep
Application granted granted Critical
Publication of DK0787492T3 publication Critical patent/DK0787492T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Dental Preparations (AREA)
  • Pyrrole Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97100145T 1990-03-16 1991-03-18 Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress DK0787492T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49453290A 1990-03-16 1990-03-16

Publications (1)

Publication Number Publication Date
DK0787492T3 true DK0787492T3 (da) 2004-02-02

Family

ID=23964864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97100145T DK0787492T3 (da) 1990-03-16 1991-03-18 Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress

Country Status (10)

Country Link
US (1) US5462946A (da)
EP (2) EP0520005B1 (da)
JP (1) JP2741427B2 (da)
AT (2) ATE157249T1 (da)
AU (1) AU644865B2 (da)
CA (1) CA2078287C (da)
DE (2) DE69127437T2 (da)
DK (1) DK0787492T3 (da)
ES (1) ES2207690T3 (da)
WO (1) WO1991013619A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US6605619B1 (en) 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
WO1997041826A1 (en) * 1996-05-07 1997-11-13 Thomas Jefferson University Use of tempol in the prevention of photoaging
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6342647B1 (en) 1998-09-09 2002-01-29 Baker Hughes Incorporated Vinyl monomer polymerization inhibition using hindered hydroxylamines
AU761674B2 (en) * 1999-06-23 2003-06-05 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
WO2002026231A1 (en) * 2000-09-26 2002-04-04 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
MXPA04011416A (es) 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Mejora del desarrollo de las cataratas y otras enfermedades oftalmicas.
AU2003277075B2 (en) * 2002-10-01 2009-12-17 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
EP1620097A4 (en) * 2003-04-25 2008-03-05 Mitos Inc PROPHYLACTIC PRE-TREATMENT WITH ANTIOXIDANTS
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
WO2004105860A2 (en) * 2003-05-29 2004-12-09 Mitos Pharmaceuticals, Inc. Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
CN100558360C (zh) * 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US20090209581A1 (en) * 2005-02-02 2009-08-20 Louis Habash Nitroxides for use in treating or preventing immunological diseases
WO2006084199A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing amyloid-related diseases
WO2006084041A2 (en) 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
CA2617962A1 (en) * 2005-08-11 2007-02-22 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Method for determining redox status of a tissue
EP1933941A2 (en) 2005-08-25 2008-06-25 Philip R. Houle Treatment systems for delivery of sensitizer solutions
US7538130B2 (en) * 2005-09-26 2009-05-26 Basf Corporation Hindered amine light stabilizer, methods of making, and compositions
US20070160642A1 (en) * 2006-01-12 2007-07-12 Pacetti Stephen D Implantable medical devices coated with a polymer-bound superoxide dismutase mimic
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
WO2008013660A2 (en) 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
WO2008067417A2 (en) * 2006-11-29 2008-06-05 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing hypercholesterolemia
WO2008101195A2 (en) * 2007-02-16 2008-08-21 Othera Holding, Inc. Drug resistance reversal in neoplastic disease
CA2680525A1 (en) * 2007-03-09 2008-09-18 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Nitroxide radical as a treatment for neurodegeneration
US7820963B2 (en) * 2007-08-06 2010-10-26 Metabolic Alayses, Inc. Method for generation and use of isotopic patterns in mass spectral data of simple organisms
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
EP2464739B1 (en) 2009-08-14 2016-01-13 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US20110130421A1 (en) * 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US20170000377A1 (en) * 2014-03-14 2017-01-05 The General Hospital Corporation System and method for imaging free radicals
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
JP7332093B2 (ja) 2018-04-16 2023-08-23 エスアンドアール ファーマチェウティチ エス．ピー．エー． 女性の生殖能力の改善のための異なる薬物動態プロファイルを有するレスベラトロルの混合物に基づく製剤の使用
CN114502546A (zh) 2019-08-01 2022-05-13 普拉特戈公司 晚期糖基化终产物的抑制剂
US12208089B2 (en) 2021-05-25 2025-01-28 Louis Habash Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals

Also Published As

Publication number Publication date
DE69133313D1 (de) 2003-10-23
US5462946A (en) 1995-10-31
ATE249829T1 (de) 2003-10-15
AU644865B2 (en) 1993-12-23
EP0520005B1 (en) 1997-08-27
DE69133313T2 (de) 2004-07-01
DE69127437D1 (de) 1997-10-02
ES2207690T3 (es) 2004-06-01
EP0520005A1 (en) 1992-12-30
EP0787492A1 (en) 1997-08-06
CA2078287A1 (en) 1991-09-17
WO1991013619A1 (en) 1991-09-19
JP2741427B2 (ja) 1998-04-15
AU7542391A (en) 1991-10-10
JPH05501114A (ja) 1993-03-04
CA2078287C (en) 1996-11-26
EP0787492B1 (en) 2003-09-17
EP0520005A4 (en) 1993-04-21
DE69127437T2 (de) 1998-02-05
ATE157249T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
DK0787492T3 (da) Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress
DK264888A (da) Fremgangsmaade til stabilisering af vanadiumtetrachlorid mod dekomponering og staliliseret vanadiumtetrachloridsammensaetning
DE69129778D1 (de) Einrichtung zur Kontrolle der Version des Chiffrierungsschlüssels
DE69115959D1 (de) Bleichende Verbindungen und Zusammensetzungen
DK461688D0 (da) Indretning til beskyttelse af oplagrede genstande
DE69224095D1 (de) Wiedergewinnbarer Strahlungsquellenträger
DK212088D0 (da) Indretning til fastlejring af tandprotese
NO914352L (no) Fremgangsmaate for behandling av brukte katodebunner
NO305398B1 (no) Tiosubstituerte nitrogenholdige heterocykliske fosfonatforbindelser, og anvendelser derav
DK627186D0 (da) Fremgangsmaade og middel til beskyttelse af vejbelaegninger mod revnedannelse
DK57385A (da) Fremgangsmaade og middel til beskyttelse af kulturplanter mod fytotoksiske bivirkninger af fenoxaprop-ethyl
DK0632225T3 (da) Beskyttelse mod blokering
FI924522L (fi) Foerfarande foer framstaellning av substituerade n-(aryl)-1,2,4-triazolopyrimidin-2-sulfonamider
DK29385D0 (da) Fremgangsmaade og indretning til eliminering af paavirkningen fra et magnetfelt og til beskyttelse mod samme
NO920157L (no) Heterocykliske hydroksylaminer
NO894845L (no) Fremgangsmaate og materialer for mikrobiell bioomdannelse av toluen og andre fenylforbindelser.
DK163805C (da) Fremgangsmaade til beskyttelse af trae og overtraek mod mikroorganismer
DK54581A (da) Middel og fremgangsmaade til stabilisering af polyolefinkompositioner mod uv-straaling
DK65082A (da) Fremgangsmaade ved beskyttelse af materialer mod nedbrydning
NO920930D0 (no) Innretning for varmebehandling av en endeloes bane
DK86792D0 (da) Indretning til behandling af baandformet fotografisk materiale
DK306578A (da) Hudplejemiddel til beskyttelse af huden mod ultraviolette straaler
NO923538L (no) Cykliske nitroner
KR930012675U (ko) 외부의 방해전파 차단장치
DK578987A (da) Straalingshaerdeligt overtraeksmateriale indeholdende et uv-absorberende middel til beskyttelse af polyvinylchlorid mod aeldning og polyvinylchlorid beskyttet paa denne maade